Abstract
Aimo et al.1 presented an elegant review of the antiviral mechanism of amiodarone, which is a commonly used antiarrhythmic drug. Although in vitro experiments demonstrated the ability of amiodarone to inhibit coronavirus, we are still wary of the authors’ recommendation to evaluate amiodarone for the treatment of coronavirus disease 2019 (COVID-19) in clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | e52 |
| Number of pages | 1 |
| Journal | European Journal of Preventive Cardiology |
| Volume | 28 |
| Issue number | 18 |
| Early online date | 12 Nov 2020 |
| DOIs | |
| Publication status | Published - 9 Feb 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver